Connect to share and comment

Novartis and GSK trade assets as pharma industry reshapes

By Caroline Copley and Paul Sandle ZURICH/LONDON (Reuters) - Novartis and GlaxoSmithKline agreed to trade more than $20 billion worth of assets on Tuesday to bolster their best businesses and exit weaker ones as the drug industry contends with healthcare spending cuts and generic competition.

In latest cycle, drugmakers use deals to narrow focus to boost prospects, satisfy shareholders

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Valeant CEO breaks the mold in building drug empire

By Rod Nickel (Reuters) - At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities. It's not the usual way of doing business in the drug sector, where research and development is often considered a company's lifeblood. But then there is little that's typical about Michael Pearson's approach to business.

In latest round of change in pharmaceuticals industry, Novartis inks deals with GSK and Lilly

GENEVA - Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly

Shake-up in pharma world as Novartis, GSK announce mega-deals

Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, unveiling multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures by the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector, GSK boost its share in vaccines and Eli Lilly strengthen its animal health unit.

Novartis revamps pharma world with mega-deals with GSK, Eli Lilly

Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, revealing multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures involving the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector and GSK seizing the chance to boost its share in vaccines.

Novartis revamps pharma world with mega-deals with GSK, Eli Lilly

Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, revealing multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures involving the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector and GSK seizing the chance to boost its share in vaccines.

Novartis, GSK, Lilly sign multibillion-dollar deals to trade business units

GENEVA - Swiss pharmaceutical giant Novartis AG announced a series of multibillion-dollar deals Tuesday with other major pharmaceutical companies that it said would reduce sales but boost profitability, while affecting some 15,000 of its employees globally. The Basel, Switzerland-based company said it has agreed to buy GlaxoSmithKline plc's cancer-drug business for $14.5 billion, plus up to $1.5 billion more if certain milestones are met, and to divest most of its vaccines business to GSK for $7.1 billion, plus royalties.

AstraZeneca cancer pipeline seen as draw for Pfizer

By Ben Hirschler LONDON (Reuters) - Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound ($101 billion) takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.

Sarepta shares soar on new hope for fatal muscle disorder drug

By Esha Dey and Natalie Grover (Reuters) - Sarepta Therapeutics Inc's shares soared 64 percent after it said that the U.S. Food and Drug Administration indicated an alternate path to approval for the company's experimental muscle disorder drug. The news provides a fresh lease of life for Sarepta, whose plans for a marketing approval the regulator deemed "premature" late last year, citing insufficient trial data.
Syndicate content